Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
Apellis Pharmaceuticals Inc APLS
News
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investigation Alert Driven Brands Holdings, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
Apellis Pharmaceuticals' stock slides 14% after company gets negative trend vote for eye treatment in Europe
Apellis Pharmaceuticals shares rally as competing eye treatment fails to impress analysts
Apellis Pharmaceuticals stock surges after investigation finds needles are potential cause of injection side effect